D4 receptors and their antagonists. 1996

M S Hadley
SmithKline Beecham Pharmaceuticals, Harlow, Essex, United Kingdom.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D050638 Receptors, Dopamine D4 A subtype of dopamine D2 receptors that has high affinity for the antipsychotic CLOZAPINE. Dopamine D4 Receptors,Dopamine D4 Receptor,Receptor, Dopamine D4,D4 Receptor, Dopamine,D4 Receptors, Dopamine
D018492 Dopamine Antagonists Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. Dopamine Antagonist,Dopamine Blocker,Dopamine Receptor Antagonist,Dopamine Receptor Antagonists,Dopaminergic Antagonist,Dopaminergic Antagonists,Antagonists, Dopamine,Antagonists, Dopamine Receptor,Antagonists, Dopaminergic,Dopamine Blockers,Antagonist, Dopamine,Antagonist, Dopamine Receptor,Antagonist, Dopaminergic,Blocker, Dopamine,Blockers, Dopamine,Receptor Antagonist, Dopamine,Receptor Antagonists, Dopamine
D065127 Dopamine D2 Receptor Antagonists Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS. Dopamine D2 Antagonist,Dopamine D2 Receptor Antagonist,Dopamine D2 Antagonists,Receptor Antagonists, Dopamine D2,Antagonist, Dopamine D2,Antagonists, Dopamine D2,D2 Antagonist, Dopamine,D2 Antagonists, Dopamine

Related Publications

M S Hadley
April 2000, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
M S Hadley
March 2015, Seminars in nephrology,
M S Hadley
June 1996, The New England journal of medicine,
M S Hadley
May 1998, European journal of pharmacology,
M S Hadley
October 2003, Current drug targets,
M S Hadley
January 1994, Advances in prostaglandin, thromboxane, and leukotriene research,
M S Hadley
January 1984, Anesteziologiia i reanimatologiia,
M S Hadley
March 2003, Mini reviews in medicinal chemistry,
M S Hadley
November 1995, Journal of neurochemistry,
Copied contents to your clipboard!